Pradžia › Plaučių vėžys › Nevada
Plaučių vėžys klinikiniai tyrimai Nevada
11 tyrimai dėl Plaučių vėžys ieško dalyvių vietose Nevada.
Miestai Nevada
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
- ir dar 25
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06312137Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Renown Regional Medical Center, Reno
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07100080A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Cancer Care Specialists, Reno
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06119581Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Renown Regional Medical Center, Reno
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-03 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
Renkami dalyviai2 fazė
18 Minutes · Visoms lytims · Atnaujinta 2026-05-05 · NCT06031688LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Carson Tahoe Regional Medical Center, Carson City
- Comprehensive Cancer Centers of Nevada - Henderson, Henderson
- OptumCare Cancer Care at Seven Hills, Henderson
- ir dar 13
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-09 · NCT06073431Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Renown Regional Medical Center, Reno
Renkami dalyviaiStebimasis tyrimas
Amžius 50 ir vyresni · Visoms lytims · Atnaujinta 2025-08-05 · NCT06122077Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.